University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Lawrence D. Kaplan

Lawrence D. Kaplan, M.D.

Director of the Lymphoma Program

Dr. Lawrence D. Kaplan, a hematologist and oncologist, is director of the Lymphoma Program at UCSF Medical Center and the HIV-Malignancies Program at San Francisco General Hospital. He is an international leader in the treatment of lymphoma and HIV-related malgnancies. In his research, Kaplan is particularly interested in developing new treatments for lymphoma and the HIV-related form of the disease.

His professional activities include serving as former chair of the Steering Committee of the AIDS-Malignancies Clinical Trials Consortium, supported by the National Cancer Institute (NCI) and serving as a member of the Cancer and Leukemia Group B, Lymphoma Committee, a national clinical research group sponsored by the NCI. Kaplan joined UCSF in 1985 and is a clinical professor of medicine. He earned a medical degree at UCLA and completed a fellowship in hematology and oncology at UCSF. He is board certified in medical oncology by the American Board of Internal Medicine.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Conditions & Treatments

More about Lawrence D. Kaplan

Additional Languages

French

Education

UCLA Medical Center 1980

Residencies

Boston City Hospital, Medicine 1983

Fellowships

UCSF Hematology/Oncology Division, Hematology/Oncology 1985

Selected Research and Publications

  1. Kaplan LD. Management of HIV-Associated Hodgkin Lymphoma: How Far We Have Come. J Clin Oncol. 2012 Nov 20; 30(33):4056-8.
  2. Kaplan LD. HIV-associated lymphoma. Best Pract Res Clin Haematol. 2012 Mar; 25(1):101-17.
  3. Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012 Aug 15; 118(16):3977-83.
  4. Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ. Left ventricular rupture due to HIV-associated T-cell lymphoma. Tex Heart Inst J. 2010; 37(4):457-60.
  5. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010 Apr 15; 115(15):3008-16.
  6. Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, Banham AH, Noy A, Kaplan LD, Sparano JA, Bhatia K, Cesarman E. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol. 2009 Oct 20; 27(30):5039-48.
  7. Lin L, Lee JY, Kaplan LD, Dezube BJ, Noy A, Krown SE, Levine AM, Yu Y, Hayward GS, Ambinder RF. Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol. 2009 May 20; 27(15):2496-502.
  8. Brinker BT, Krown SE, Lee JY, Cesarman E, Chadburn A, Kaplan LD, Henry DH, Von Roenn JH. Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1; 112(5):1083-8.
  9. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008 Jan; 14(1):59-66.
  10. Behler CM, Kaplan LD. Advances in the management of HIV-related non-Hodgkin lymphoma. Curr Opin Oncol. 2006 Sep; 18(5):437-43.
  11. Dunleavy K, Wilson WH, Kaplan LD. The case for rituximab in AIDS-related lymphoma. Blood. 2006 Apr 1; 107(7):3014-5.
  12. Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood. 2006 Jan 1; 107(1):13-20.
  13. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1; 106(5):1538-43.
  14. Michaels MG, Kaufman C, Volberding PA, Gupta P, Switzer WM, Heneine W, Sandstrom P, Kaplan L, Swift P, Damon L, Ildstad ST. Baboon bone-marrow xenotransplant in a patient with advanced HIV disease: case report and 8-year follow-up. Transplantation. 2004 Dec 15; 78(11):1582-9.
  15. Kaplan LD. Current status of the treatment of HIV-associated lymphoma. Clin Adv Hematol Oncol. 2004 Jan; 2(1):28-9.
  16. Kaplan LD, Afridi NA, Holmvang G, Zukerberg LR. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2003. A 44-year-old man with HIV infection and a right atrial mass. N Engl J Med. 2003 Oct 2; 349(14):1369-77.
  17. Gates AE, Kaplan LD. Biology and management of AIDS-associated non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2003 Jun; 17(3):821-41.
  18. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park). 2002 May; 16(5):657-65; discussion 665, 668-70.
  19. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park). 2002 Apr; 16(4):441-51, 456, 459.
  20. Kaplan LD. Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care. Am J Med. 2002 Mar; 112(4):320-1.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California